EE200200247A - Polütsükloalküülpuriinid kui adenosiiniretseptoriantagonistid - Google Patents

Polütsükloalküülpuriinid kui adenosiiniretseptoriantagonistid

Info

Publication number
EE200200247A
EE200200247A EEP200200247A EEP200200247A EE200200247A EE 200200247 A EE200200247 A EE 200200247A EE P200200247 A EEP200200247 A EE P200200247A EE P200200247 A EEP200200247 A EE P200200247A EE 200200247 A EE200200247 A EE 200200247A
Authority
EE
Estonia
Prior art keywords
polycycloalkyl
purines
receptor antagonists
adenosine receptor
adenosine
Prior art date
Application number
EEP200200247A
Other languages
English (en)
Inventor
Lee Ensinger Carol
F. Kiesman William
E. Dowling James
Kumaravel Gnanasambandam
C. Petter Russell
Xi Chang He
Chung Lin Ko
Original Assignee
Biogen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen, Inc. filed Critical Biogen, Inc.
Publication of EE200200247A publication Critical patent/EE200200247A/et
Publication of EE05365B1 publication Critical patent/EE05365B1/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/22—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
EEP200200247A 1999-11-12 2000-11-13 Poltskloalklpuriinid kui adenosiiniretseptori antagonistid EE05365B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16519199P 1999-11-12 1999-11-12
PCT/US2000/031058 WO2001034610A1 (en) 1999-11-12 2000-11-13 Polycycloalkylpurines as adenosine receptor antagonists

Publications (2)

Publication Number Publication Date
EE200200247A true EE200200247A (et) 2003-06-16
EE05365B1 EE05365B1 (et) 2010-12-15

Family

ID=22597852

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200247A EE05365B1 (et) 1999-11-12 2000-11-13 Poltskloalklpuriinid kui adenosiiniretseptori antagonistid

Country Status (35)

Country Link
US (5) US6649600B1 (et)
EP (3) EP2070930A1 (et)
JP (1) JP2003513982A (et)
KR (2) KR20080027971A (et)
CN (2) CN101255162A (et)
AT (1) ATE424403T1 (et)
AU (1) AU784556B2 (et)
BG (1) BG65720B1 (et)
BR (1) BR0015545A (et)
CA (1) CA2390496A1 (et)
CY (1) CY1110512T1 (et)
CZ (1) CZ20021614A3 (et)
DE (1) DE60041710D1 (et)
DK (1) DK1230243T3 (et)
EA (1) EA005211B1 (et)
EE (1) EE05365B1 (et)
ES (1) ES2323357T3 (et)
GE (1) GEP20043303B (et)
HK (1) HK1049155B (et)
IL (1) IL149487A0 (et)
IS (1) IS6379A (et)
ME (1) MEP42208A (et)
MX (1) MXPA02004796A (et)
NO (1) NO328956B1 (et)
NZ (2) NZ527917A (et)
PL (1) PL206890B1 (et)
PT (1) PT1230243E (et)
RS (1) RS50381B (et)
SI (1) SI1230243T1 (et)
SK (1) SK287311B6 (et)
TR (1) TR200201260T2 (et)
TW (1) TWI272270B (et)
UA (1) UA77391C2 (et)
WO (1) WO2001034610A1 (et)
ZA (1) ZA200203701B (et)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2390496A1 (en) * 1999-11-12 2001-05-17 Biogen, Inc. Polycycloalkylpurines as adenosine receptor antagonists
PL198156B1 (pl) * 1999-11-12 2008-05-30 Biogen Idec Ma Ksantyny podstawione w pozycji 8, sposób ich wytwarzania i ich zastosowanie oraz kompozycja farmaceutyczna
UA80258C2 (en) * 2001-09-06 2007-09-10 Biogen Inc Methods of treating pulmonary disease
DE10145193C1 (de) 2001-09-13 2003-03-13 Sachtler Gmbh & Co Kg Körpermontierbares Kameratragesystem mit einem multifunktionalen Verbund elektrischer Komponenten
RS107404A (sr) * 2002-06-12 2007-02-05 Biogen Idec Ma Inc., Metod lečenja ishemične povrede izazvane poremećajem perfuzije upotrebom antagonista adenozinskog receptora
WO2004009091A1 (en) 2002-06-17 2004-01-29 Glaxo Group Limited Purine derivatives as liver x receptor agonists
WO2004009594A2 (en) * 2002-07-19 2004-01-29 Aryx Therapeutics Xanthine derivatives having adenosine a1-receptor antagonist properties
JP2006518390A (ja) * 2003-02-19 2006-08-10 エンダシア，インコーポレイテッド Ａ１アデノシンレセプターアンタゴニスト
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
AU2004233852A1 (en) * 2003-04-25 2004-11-11 Novacardia, Inc. Method of improved diuresis in individuals with impaired renal function
US7247639B2 (en) 2003-06-06 2007-07-24 Endacea, Inc. A1 adenosine receptor antagonists
CA2612338C (en) 2005-06-17 2015-02-03 Apogee Biotechnology Corporation Sphingosine kinase inhibitors
WO2007059330A2 (en) * 2005-11-17 2007-05-24 Medkura Inc. Cubane nucleoside analogs
CA2648281A1 (en) * 2006-04-06 2007-10-18 Novacardia, Inc. Co-administration of adenosine a1 receptor antagonists and anticonvulsants
CN101085785B (zh) * 2006-06-06 2011-09-21 中国科学院上海药物研究所 用于治疗乙型肝炎的嘌呤类化合物及其制备方法和用途，以及包括该化合物的组合物
EP2035009A1 (en) * 2006-06-16 2009-03-18 Novacardia, Inc. Prolonged improvement of renal function comprising infrequent administration of an aa1ra
US8685471B2 (en) * 2006-07-17 2014-04-01 Tyratech, Inc. Compositions and methods for controlling insects
WO2008121882A1 (en) * 2007-03-29 2008-10-09 Novacardia, Inc. Improved methods of administration of adenosine a1 receptor antagonists
WO2008121893A1 (en) * 2007-03-29 2008-10-09 Novacardia, Inc. Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist
WO2009086077A2 (en) 2007-12-21 2009-07-09 Endacea, Inc. A1 adenosine receptor antagonists
WO2009152458A1 (en) * 2008-06-13 2009-12-17 Biogen Idec Ma Inc. Liquid formulation suitable for infusion comprising an adenosine receptor antagonist for treating heart failure and renal insufficiency.
WO2010011917A1 (en) * 2008-07-25 2010-01-28 Glaxosmithkline Llc SEH AND 11β-HSD1 DUAL INHIBITORS
WO2011063268A2 (en) 2009-11-19 2011-05-26 Biogen Idec Ma Inc Novel synthetic methods
BR112012013299A2 (pt) * 2009-12-04 2019-09-24 Commw Scient Ind Res Org polímero,uso de um composto ,uso de uma polímero, processo para produzir im polímero, folha,fibra ou filme e mescla de polímero
CN101709034B (zh) * 2009-12-14 2017-05-31 大连九信精细化工有限公司 双环[2.2.2]辛烷‑1，4‑二羧酸单甲酯的合成方法
AR084457A1 (es) * 2010-12-22 2013-05-15 Lundbeck & Co As H Derivados de biciclo[3,2,1]octilamida
AU2012275499A1 (en) 2011-06-27 2013-12-19 Kyorin Pharmaceutical Co., Ltd. Bridged bicyclic compounds for the treatment of bacterial infections
US8962660B2 (en) 2013-03-14 2015-02-24 Bristol-Myers Squibb Company Oxabicyclo [2.2.2] acid GPR120 modulators
AU2014244482B2 (en) * 2013-03-14 2018-01-25 Bristol-Myers Squibb Company Bicyclo [2.2.2] acid GPR120 modulators
LT6401B (lt) 2015-07-28 2017-06-12 Vilniaus Universitetas Karboanhidrazės selektyvūs inhibitoriai
WO2017127306A1 (en) 2016-01-18 2017-07-27 Arisan Therapeutics Adamatane derivatives for the treatment of filovirus infection
US10633315B2 (en) 2016-10-19 2020-04-28 Eastman Chemical Company Synthesis of bicyclo[2.2.2]octanes
WO2019018185A1 (en) 2017-07-15 2019-01-24 Arisan Therapeutics Inc. ENANTIOMERICALLY PURE ADAMATANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTIONS
DK3682881T3 (da) 2017-09-14 2026-05-11 Daiichi Sankyo Co Limited Forbindelse med cyklisk struktur
WO2019075004A1 (en) 2017-10-11 2019-04-18 Eastman Chemical Company SYNTHESIS OF BICYCLO [2.2.2] OCTANE DERIVATIVES
WO2019089667A1 (en) 2017-11-01 2019-05-09 Bristol-Myers Squibb Company Bridged bicyclic compounds as farnesoid x receptor modulators
KR102788997B1 (ko) 2018-09-18 2025-03-28 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 옥사비시클로 산
US10836899B2 (en) 2018-12-13 2020-11-17 Eastman Chemical Company Polyesters with specified crystallization half-times

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0011399A1 (en) * 1978-11-11 1980-05-28 FISONS plc N-substituted theophyllines, processes for their preparation and pharmaceutical compositions containing them
DE8817122U1 (de) * 1988-12-22 1993-02-04 Boehringer Ingelheim Kg, 55218 Ingelheim Neue Xanthinderivate mit Adenosinantogenistischer Wirkung
US5290782A (en) * 1989-09-01 1994-03-01 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
JPH06102662B2 (ja) 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
JP2988711B2 (ja) 1989-10-20 1999-12-13 協和醗酵工業株式会社 縮合プリン誘導体
DE4019892A1 (de) 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
CA2061544A1 (en) * 1991-02-25 1992-08-26 Fumio Suzuki Xanthine compounds
JPH04270222A (ja) * 1991-02-25 1992-09-25 Kyowa Hakko Kogyo Co Ltd 脳機能改善剤
JPH0559056A (ja) * 1991-02-25 1993-03-09 Kyowa Hakko Kogyo Co Ltd キサンチン誘導体
JPH04346986A (ja) * 1991-05-23 1992-12-02 Kyowa Hakko Kogyo Co Ltd トリチウム標識化されたキサンチン誘導体
JP3115128B2 (ja) * 1991-11-08 2000-12-04 協和醗酵工業株式会社 キサンチン誘導体
ATE180482T1 (de) * 1991-11-08 1999-06-15 Kyowa Hakko Kogyo Kk Xanthinderivate zur behandlung der demenz
US5336769A (en) * 1992-02-17 1994-08-09 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
US5342841A (en) * 1992-03-12 1994-08-30 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
JPH0616668A (ja) * 1992-03-12 1994-01-25 Kyowa Hakko Kogyo Co Ltd キサンチン誘導体
TW252044B (et) 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
US5384176A (en) * 1992-12-11 1995-01-24 Zimmerman; Richard C. Phenolic acid sulfate esters for prevention of marine biofouling
WO1994016702A1 (fr) * 1993-01-26 1994-08-04 Kyowa Hakko Kogyo Co., Ltd. Medicament contre l'elimination irreguliere des matieres fecales
US5395836A (en) * 1993-04-07 1995-03-07 Kyowa Hakko Kogyo Co., Ltd. 8-tricycloalkyl xanthine derivatives
JP3729874B2 (ja) * 1993-04-07 2005-12-21 協和醗酵工業株式会社 キサンチン誘導体
US5446046A (en) * 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics
WO1998057644A1 (en) * 1997-06-16 1998-12-23 Kyowa Hakko Kogyo Co., Ltd. Preventive and remedy for drug-induced nephropathy
WO1998057645A1 (en) * 1997-06-16 1998-12-23 Kyowa Hakko Kogyo Co., Ltd. Hepatic edema remedy
DE19816857A1 (de) * 1998-04-16 1999-10-21 Boehringer Ingelheim Pharma Neue unsymmetrisch substituierte Xanthin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AU3757999A (en) 1998-04-24 1999-11-16 Biogen, Inc. Adenosine a1 receptor antagonist containing composition and method for restoringdiuretic and renal function
EP0955301A3 (en) * 1998-04-27 2001-04-18 Pfizer Products Inc. 7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylcholine receptors
WO2000001388A1 (en) 1998-07-02 2000-01-13 Kyowa Hakko Kogyo Co., Ltd. Remedies for diabetes
CA2390496A1 (en) * 1999-11-12 2001-05-17 Biogen, Inc. Polycycloalkylpurines as adenosine receptor antagonists
PL198156B1 (pl) * 1999-11-12 2008-05-30 Biogen Idec Ma Ksantyny podstawione w pozycji 8, sposób ich wytwarzania i ich zastosowanie oraz kompozycja farmaceutyczna
EP1338595B1 (en) * 2002-02-25 2006-05-03 Eisai Co., Ltd. Xanthine derivatives as DPP-IV inhibitors
WO2004009594A2 (en) * 2002-07-19 2004-01-29 Aryx Therapeutics Xanthine derivatives having adenosine a1-receptor antagonist properties
US7129239B2 (en) * 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
HRP20130406T1 (hr) * 2004-02-14 2013-06-30 Glaxosmithkline Intellectual Property Development Limited Medikamenti s aktivnošä†u prema receptoru hm74a

Also Published As

Publication number Publication date
RS50381B (sr) 2009-11-10
US20060252730A1 (en) 2006-11-09
IL149487A0 (en) 2002-11-10
EP1230243B1 (en) 2009-03-04
DK1230243T3 (da) 2009-06-15
CN100390178C (zh) 2008-05-28
MXPA02004796A (es) 2007-01-30
EE05365B1 (et) 2010-12-15
ZA200203701B (en) 2004-02-23
KR20080027971A (ko) 2008-03-28
NZ519426A (en) 2003-08-29
GEP20043303B (en) 2004-01-12
CZ20021614A3 (cs) 2002-07-17
HK1049155B (en) 2009-11-06
US7579354B2 (en) 2009-08-25
TR200201260T2 (tr) 2002-09-23
US20040067966A1 (en) 2004-04-08
UA77391C2 (en) 2006-12-15
BG106762A (en) 2003-01-31
HK1049155A1 (en) 2003-05-02
PL206890B1 (pl) 2010-10-29
US6649600B1 (en) 2003-11-18
YU33802A (sh) 2006-01-16
AU784556B2 (en) 2006-05-04
TWI272270B (en) 2007-02-01
BR0015545A (pt) 2002-08-06
PL356033A1 (en) 2004-06-14
NO20022238D0 (no) 2002-05-10
PT1230243E (pt) 2009-06-12
EP2305684A1 (en) 2011-04-06
ATE424403T1 (de) 2009-03-15
US20090221821A1 (en) 2009-09-03
KR20020049050A (ko) 2002-06-24
MEP42208A (en) 2011-02-10
CN101255162A (zh) 2008-09-03
JP2003513982A (ja) 2003-04-15
DE60041710D1 (de) 2009-04-16
SK6632002A3 (en) 2003-02-04
EP2070930A1 (en) 2009-06-17
BG65720B1 (bg) 2009-08-31
SI1230243T1 (sl) 2009-08-31
EA005211B1 (ru) 2004-12-30
NO328956B1 (no) 2010-06-28
NO20022238L (no) 2002-07-12
EP1230243A1 (en) 2002-08-14
CA2390496A1 (en) 2001-05-17
NZ527917A (en) 2005-03-24
AU1600001A (en) 2001-06-06
US20070015732A1 (en) 2007-01-18
SK287311B6 (sk) 2010-06-07
EA200200560A1 (ru) 2002-10-31
KR100863761B1 (ko) 2008-10-16
CN1402729A (zh) 2003-03-12
IS6379A (is) 2002-05-10
CY1110512T1 (el) 2015-04-29
WO2001034610A1 (en) 2001-05-17
ES2323357T3 (es) 2009-07-14

Similar Documents

Publication Publication Date Title
EE05365B1 (et) Poltskloalklpuriinid kui adenosiiniretseptori antagonistid
CY1106560T1 (el) Ανταγωνιστες υποδοχεα αδενοσινης και μεθοδοι κατασκευης και χρησης αυτων
WO1997020823A3 (en) 2-amino quinazoline derivatives as npy receptor antagonists
NL300006I2 (nl) Imidazolylalkeenzuurderivaten.
TNSN05045A1 (en) Indole or benzimidazole derivatives for modulating ikappab kinase
BG101715A (bg) Тетрациклени спиросъединения,метод за тяхното получаване и приложението им като 5нт долу 1d рецепторни антагонисти
DE60230683D1 (de) 3,6-disubstituierte azabicyclo-3.1.0 hexan-derivat
HUT61022A (en) Process for producing 8-substituted purine derivatives functioning as selective adenosine receptor, as well as pharmaceutical compositions comprising same as active ingredient
DE69834500D1 (de) Xanthinderivative zur behandlung von hirnischämie
CA2275686A1 (en) Isoquinolinamine and phthalazinamine derivatives which interact with crf receptors

Legal Events

Date Code Title Description
HC1A Change of owner name
HE1A Change of address
KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20111113